Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

Background: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent kinase 4/6 pathway. We prospectively i...

Full description

Bibliographic Details
Main Authors: Ballestrero, A. (Author), Benelli, M. (Author), Bergqvist, M. (Author), Bernardo, A. (Author), Bliss, J.M (Author), Bonetti, A. (Author), Breast International Group and PYTHIA Collaborators (Author), Cameron, D. (Author), Colleoni, M. (Author), Davies, D.M (Author), De Swert, H. (Author), Duhoux, F.P (Author), Fumagalli, D. (Author), Gebhart, G. (Author), Henry, S. (Author), Hilbers, F.S (Author), Ignatiadis, M. (Author), International Breast Cancer Study Group (Author), Jerusalem, G. (Author), Kammler, R. (Author), Loi, S. (Author), MacPherson, I.R (Author), Maibach, R. (Author), Malorni, L. (Author), McCartney, A. (Author), Migliaccio, I. (Author), Neven, P. (Author), Papadimitriou, K. (Author), Piccart, M. (Author), Regan, M.M (Author), Ruepp, B. (Author), Seles, E. (Author), Thomson, A. (Author), Tyekucheva, S. (Author), Zoppoli, G. (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
adult
aged
Article
Breast cancer
cancer combination chemotherapy
cancer patient
cancer prognosis
clinical feature
controlled study
drug dose sequence
enzyme activity
enzyme linked immunosorbent assay
female
follow up
fulvestrant
Fulvestrant
hormone receptor-positive, HER2-negative breast cancer
human
limit of detection
major clinical study
metastatic breast cancer
multicenter study
multiple cycle treatment
palbociclib
Palbociclib
phase 2 clinical trial
postmenopause
Prognostic factors
progression free survival
prospective study
Serum markers
thymidine kinase
Thymidine kinase
treatment duration
treatment outcome
treatment response
unspecified side effect
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items